Madhu Chopra

Assistant Professor

Molecular Modelling and Anticancer Drug Development
Email: mchopradu@gmail.commchopra@acbr.du.ac.in

Dr. Madhu Chopra has been working on the design and synthesis of peptides and peptide-mimetics D to be targeted specifically to the cancers. We have been able to design lead compounds in our lab for various medicinal purposes. E. g. CCK antagonists have been developed and checked for their in-vitro as well as in-vivo potential. The developed lead compounds would be improved for their efficacy and affinity using computational tools and will be retested in the laboratory to give novel antagonists. Other projects on development of COX-2 and HDAC inhibitors have also given several lead compounds whose structure is being refined computational which will be finally synthesized to give more potent inhibitors.

Natural products that have always been sources of wealth of drug molecules need to be explored in more scientific way. My future research interests are to exploit my ability to highest extent to screen or to isolate drugs from our natural fauna and flora for medical application, which is not available anywhere in the world. We have initiated screening programme for evaluating the natural resources.

They have also been working towards developing diagnostics for tuberculosis for rapid and fast diagnosis of the disease. New methodologies are being developed in our laboratory for successful delivery of cytotoxic drug like Doxorubicin, Methotrexate etc. through nanoparticle mediated drug delivery systems.

Computer aided drug design: Pharmacophore based drug design in our laboratory has resulted in development of potent compounds as cholecystokinin-B/gastrin receptor antagonists, Cyclooxygenase-2 and HDAC enzyme inhibitors and in silico screening of the designed ligands has been done for development of more potent compounds.

Natural Product Screening for anticancer drug development: Three compounds have been isolated from Boerhavia diffusa using activity-guided fractionation using column followed by HPLC and the compounds have been identified and one of them is a novel compound and is showing activity towards human glioma cell line. The detailed mechanism of action of all the three compounds is underway in the laboratory.

Design, Synthesis and Evaluation of non Peptidic CCK-B receptor Specific Antagonists for targeting CCK-B receptor expressing Tumours. 25 compounds have been synthesized and evaluated for their in vitro binding affinities and one of the compounds has been targeted to in vivo receptors in animal studies.

Ongoing Projects:

  1. Creation of Bioinformatics Infrastructure Facility (BIF) at ACBR, DBT, 2006-2012
  1. “Development of Anticancer Therapeutics: Targeting drug loaded nanocarriers to CD44, A Hyaluroan Receptor” Sanctioned by University of Delhi, 2009.
  1. Structure Based Design, Synthesis and Evaluation of Histone Deacetylase Inhibitors as Potent Antitumour Agents, Sanctioned by DBT, 2008.
  1. Biodegradable Nanogels as Potential Drug Delivery Carriers for Development of Target Specific Chemotherapeutic from UGC, 2008.
  1. Isolation, Chemical Characterization and Biological evauation of Potential Anticancer Agents From Boerhavia diffusa Project Proposal sanctioned by ICMR, 2007.
Selected Recent Publications:
  1. In vitro isolation and characterization of biolarvicidal compounds from micropropagated plants of Spilanthes acmella Vibha Pandey, Madhu Chopra, Veena Agrawal, Parasitol Res. DOI 10. 1007/s00436-010-2056-y., 2010.

  2. Inhibition of Human Cervical Cancer Cell Growth by Ethanolic Extract of Boerhaavia diffusa Linn.(Punarnava) Root. Rakhi Srivastava; Daman Saluja; Bilikere S. Dwarakanath; Madhu Chopra* Evidence-based Complementary and Alternative Medicine doi: 10. 1093/ecam/nep223, 2010.

  3. Synthesis and evaluation of Ciprofloxacin derivatives as diagnostic tools for bacterial infection by Staphylococcus Aureus. Saurabh Dahiya, Krishna Chuttani, Roop K. Khar, Daman Saluja, Anil K. Mishra* and Madhu Chopra*, Metallomics, 1, 409 – 417, DOI: 10. 1039/b908474f, 2009.

  4. Effect of Varying Chain Length between P1 and P1' Position of Tripeptidomimics on Activity of Angiotensin Converting Enzyme Inhibitors. Snehlata, Ishwar Dutt Vats, Madhu Chopra, Parbati Biswas, Santosh Pasha, Bioorganic Medicinal Chemistry Letters, 19, 4364 – 4366, 2009.

  5. Autoacetylation of Purified Calreticulin Transacetylase Utilizing Acetoxycoumarin as the Acetyl Group Donor Seema Bansal, Prija Ponnan, Hanumantharao G. Raj, Susan T. Weintraub, Madhu Chopra, Ranju Kumari, Daman Saluja et. al. Applied Biochemistry and Biotechnology, 157, 285–298, 2009.

  6. Molecular Modeling Study on Chemically Diverse Series of Cycloogenase-2 Selective Inhibitors: Generation of Predictive Pharmacophore Model using Catalyst, Madhu Chopra*, Ruby Gupta, Swati Gupta and Daman Saluja Journal of Molecular Modeling, 14, 1087–1099, 2008.

  7. Ligand-Based Molecular Modeling Study on Chemically Diverse Series of Cholecystokinin-B/Gastrin Receptor Antagonists: Generation of Predictive Model Madhu Chopra* and Anil K. Mishra, Journal of Chemical Information and Modeling, 45, 1934-1942, 2005.

  8. Convenient Route for Synthesis of Bifunctional Chelating Agent: 1-(p-Aminobenzyl)ethylene diaminetetramethylphosphonic acid-Folate Conjugate (Am-Bz-EDTMP-folate), Anil Kumar Mishra, Madhu Chopra* and Vinay Jain, Chemistry Letters, Vol. 34, No. 8, 1098-1099, 2005.

  9. Novel 99mTc radiolabeled quinazolinone derivative [Qn-In]: synthesis, evaluation and biodistribution studies in mice and rabbit. Saroj Kumari, Neetu Kalra, Pushpa Mishra, Krishna Chutani, Anil Mishra and Madhu Chopra*, Nuclear medicine and Biology, Vol. 31, 1087-1095, 2004.

  10. Synthesis of novel bifunctional Schiff-base ligands derived from condensation of 1-(pnitrobenzyl) ethylenediamine and 2-(p-nitrobenzyl)-3-monooxo-1, 4, 7-triazaheptane with salicylaldehyde. Anil Kumar Mishra, Puja Panwar, Madhu Chopra, Rakesh Kumar Sharma, Jean-Francois Chatal. New Journal of Chemistry, 7, 1054, 2003.